Coagulation Protein Disorders - 25 Studies Found
Completed |
: Epidemiology and Immunology of Hemophilia A Inhibitors :
: 2000-05-25 |
Completed |
: Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A :
: 2008-10-29 :
|
Completed |
: Cooperative Study of Factor VIII Inhibitors :
|
Not yet recruiting |
: Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies : Hemophilia : 2017-05-16 : Other: Non interventionnal study A query form to all concerned patients by each investigating centre wil |
Available |
: An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors : Hemophilia A : 2017-05-12 : Biological: Emicizumab Participants will receive emicizumab at a loading dose of 3 milligrams per kilogr |
Not yet recruiting |
: DDAVP vs. Exercise : Children With Mild Hemophilia A : 2017-04-27 :
|
Not yet recruiting |
: Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies : Hemophilia A : 2017-03-31 : Biological: Recombinant coagulation factor (rFVIIIFc) rFVI |
Recruiting |
: Alphanate in Immune Tolerance Induction Therapy : Hemophilia A, Congenital : 2017-03-23 : Biological: Alphanate Daily intravenous infusion of Alphanate 100 IU/kg/day |
Not yet recruiting |
: A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment : Hemophilia A : 2017-03-10 : Biological: rFVIIIFc rFVIIIFc 200 IU/kg/day in ITI Period and 50 or 100 IU/kg (adjusted according to Inv |
Recruiting |
: Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency : Factor VII Deficiency : 2017-03-04 :
|